BCL6: The Master Regulator of Germinal Center Reactions

BCL6 (B cell lymphoma 6) is a transcriptional repressor that serves as the master regulator of the germinal center (GC) reaction. Without BCL6, germinal centers cannot form and affinity maturation cannot occur. Understanding BCL6 biology is essential for understanding both normal immune function and B cell lymphoma pathogenesis.

BCL6 Expression and Function in Normal B Cells

BCL6 is expressed at high levels in germinal center B cells—both centroblasts and centrocytes—and is essential for their formation and maintenance. BCL6 functions as a transcriptional repressor, binding to target genes and silencing them through recruitment of histone deacetylases and other co-repressors.

BCL6's key targets include BLIMP-1 (PRDM1), which drives plasma cell differentiation; IRF4, another differentiation factor; CDKN1A (p21) and CDKN2A (p16), which limit proliferation; ATR and other DNA damage response genes; and TP53, the tumor suppressor. By silencing these genes, BCL6 creates a permissive state for extensive proliferation and somatic hypermutation.

BCL6 and the DNA Damage Tolerance Program

One of BCL6's most important functions is suppressing the normal DNA damage response in centroblasts. This is necessary because somatic hypermutation introduces thousands of mutations per cell division—which would normally trigger apoptosis through ATM/ATR-mediated DNA damage responses. BCL6 suppresses these checkpoints, allowing centroblasts to tolerate the mutagenic load of SHM while continuing to proliferate.

This is a double-edged sword: while essential for antibody maturation, BCL6-mediated DNA damage tolerance also creates an environment where oncogenic mutations can accumulate, contributing to lymphoma development.

BCL6 Regulation

BCL6 itself is tightly regulated. It is expressed when B cells enter the germinal center reaction and is downregulated as B cells differentiate into plasma cells or memory cells. CD40 signaling (from T cells), toll-like receptor activation, and plasma cell differentiation signals all downregulate BCL6. BCL6 also autoregulates its own expression, creating complex feedback dynamics.

BCL6 in Lymphoma and as a Therapeutic Target

BCL6 is frequently rearranged or overexpressed in diffuse large B cell lymphoma and other aggressive B cell lymphomas. Small molecule BCL6 inhibitors are in clinical development, with the goal of pushing lymphoma cells toward differentiation or apoptosis by allowing BLIMP-1 and other BCL6 targets to be expressed.

Read more about B cell transcription factors on our blog.